title: Budesonide in the treatment of inflammatory bowel disease.
abstract: Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, features recurrent episodes of inflammation of the GI tract. The treatment of inflammatory bowel disease is aimed at breaking the cycle of relapsing and remitting inflammation by inducing and maintaining remission. Systemically active conventional corticosteroids have long played a role in the induction of remission in both Crohn's disease and ulcerative colitis, however, their long-term use can lead to adverse systemic effects. Budesonide, a synthetic steroid, has potent local anti-inflammatory effects and limited systemic bioavailability making it an appealing therapeutic option. Ulcerative colitis with predominantly distal disease may be treated with topical budesonide, however, novel oral controlled-release formulations have also been developed to allow for treatment of the entire colon. This article summarizes the use of budesonide in the management of inflammatory bowel disease.
authors.affiliation: Department of Pediatrics, Dalhousie University and IWK Health Centre, Halifax, NS, Canada.
authors.forename: Jason
authors.initials: J
authors.lastname: Silverman
authors.forename: Anthony
authors.initials: A
authors.lastname: Otley
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D057285:Precision Medicine; D012074:Remission Induction
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D019819:Budesonide